feat: Signal CGM Level 1 foundation — calculator, audit logger, payer rules, license
This commit is contained in:
Kisa
parent
346a1fb58e
commit
69dcbb36c1
3 changed files with 2109 additions and 0 deletions
939
Projects/DMEPOS/dmepos-research-v3.md
Normal file
939
Projects/DMEPOS/dmepos-research-v3.md
Normal file
|
|
@ -0,0 +1,939 @@
|
|||
# DMEPOS Market Research — v3
|
||||
### Signal CGM | STTIL Solutions LLC | April 2026
|
||||
|
||||
> **Scope:** CGM-focused DMEPOS market analysis for Signal CGM positioning,
|
||||
> asset sale context, and go-to-market strategy. Includes structural market
|
||||
> dynamics, regulatory pressures, patient outcome evidence, and a balanced
|
||||
> view that includes criticism of the sector.
|
||||
|
||||
---
|
||||
|
||||
## Table of Contents
|
||||
|
||||
1. [The Fundamental Business Paradox](#1-the-fundamental-business-paradox)
|
||||
2. [Market Size and Supplier Landscape](#2-market-size-and-supplier-landscape)
|
||||
3. [The Denial Crisis — Industry-Wide](#3-the-denial-crisis--industry-wide)
|
||||
4. [CGM-Specific Denial Anatomy](#4-cgm-specific-denial-anatomy)
|
||||
5. [The Hidden Cost: Free Product and Write-Offs](#5-the-hidden-cost-free-product-and-write-offs)
|
||||
6. [Payment Model Disruption: CGM Goes Rental](#6-payment-model-disruption-cgm-goes-rental)
|
||||
7. [The UHC / Synapse Health Wrinkle](#7-the-uhc--synapse-health-wrinkle)
|
||||
8. [Systematic Squeeze: Are Small Suppliers Being Pushed Out?](#8-systematic-squeeze-are-small-suppliers-being-pushed-out)
|
||||
9. [Patient Outcomes: Why DMEPOS Channel Matters](#9-patient-outcomes-why-dmepos-channel-matters)
|
||||
10. [The Regulatory Stack — 2026 Urgency Drivers](#10-the-regulatory-stack--2026-urgency-drivers)
|
||||
11. [The Workload Impact Model](#11-the-workload-impact-model)
|
||||
12. [Contrary Opinions — The Other Side of the Story](#12-contrary-opinions--the-other-side-of-the-story)
|
||||
13. [Signal CGM Positioning Summary](#13-signal-cgm-positioning-summary)
|
||||
|
||||
---
|
||||
|
||||
## 1. The Fundamental Business Paradox
|
||||
|
||||
No other class of healthcare provider operates the way DMEPOS suppliers do.
|
||||
|
||||
A physician bills after the visit. A hospital bills after discharge. A pharmacy
|
||||
fills a prescription and collects at the counter. But a DMEPOS supplier —
|
||||
whether providing a CGM system, a wheelchair, or an insulin pump — must first
|
||||
**purchase the equipment, deliver it to the patient, and then hope the claim
|
||||
gets paid** on the back end.
|
||||
|
||||
The financial exposure is not theoretical. It is structural.
|
||||
|
||||
```
|
||||
DMEPOS CASH FLOW MODEL vs. OTHER HEALTHCARE PROVIDERS
|
||||
──────────────────────────────────────────────────────────────────────
|
||||
|
||||
Physician / Hospital / Pharmacy
|
||||
─────────────────────────────────
|
||||
Service Rendered → Claim Submitted → Payment Received
|
||||
▶ No capital at risk until claim is submitted
|
||||
|
||||
DMEPOS Supplier
|
||||
─────────────────────────────────
|
||||
Equipment Purchased ──▶ Supplier Pays (Day 0)
|
||||
│
|
||||
▼
|
||||
Equipment Delivered to Patient ──▶ Patient Has Product
|
||||
│
|
||||
▼
|
||||
Claim Submitted ──▶ Payer Reviews
|
||||
│
|
||||
├──▶ APPROVED → Payment received (30–90 days later)
|
||||
│
|
||||
└──▶ DENIED → Supplier absorbs full product cost
|
||||
+ delivery cost
|
||||
+ staff time on appeal
|
||||
+ often provides continuity product anyway
|
||||
(see Section 5)
|
||||
|
||||
──────────────────────────────────────────────────────────────────────
|
||||
Capital risk window: Day 0 through Day 90+ on every single order.
|
||||
```
|
||||
|
||||
This model exists because Medicare Part B (which covers DMEPOS) was designed
|
||||
around a "reasonable and necessary" determination that happens *after* delivery.
|
||||
Suppliers are not hospitals with credit lines and cost-shifting mechanisms. Most
|
||||
are small businesses — often 5 to 50 employees — absorbing full product cost
|
||||
risk on every shipment.
|
||||
|
||||
The practical consequence: **documentation problems in the referring physician's
|
||||
office or payer system become the supplier's financial liability, not the
|
||||
physician's.** The supplier delivered the product in good faith; the payer
|
||||
denies the claim for reasons entirely outside the supplier's control.
|
||||
|
||||
---
|
||||
|
||||
## 2. Market Size and Supplier Landscape
|
||||
|
||||
### The CGM Opportunity
|
||||
|
||||
| Metric | Figure | Source |
|
||||
|--------|--------|--------|
|
||||
| Medicare-enrolled DMEPOS suppliers billing CGM | ~7,500 | Signal CGM TAM estimate |
|
||||
| CMS projected CGM beneficiaries by 2028 | 3.2 million | CMS projections |
|
||||
| Medicare Part B CGM + glucose monitor spend | ~$278.5M improper payments alone | CMS 2024 data |
|
||||
| DMEPOS total Medicare spend (all categories) | $7B+ annually | OIG |
|
||||
|
||||
### Supplier Count: A Shrinking Base
|
||||
|
||||
```
|
||||
TRADITIONAL HME/DMEPOS SUPPLIER LOCATIONS — MEDICARE (2013–2024)
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
2013 │████████████████████████████████████████ ~13,000
|
||||
2014 │███████████████████████████████████████
|
||||
2015 │██████████████████████████████████████
|
||||
2016 │████████████████████████████████████
|
||||
2017 │███████████████████████████████████
|
||||
2018 │█████████████████████████████████
|
||||
2019 │███████████████████████████████
|
||||
2020 │█████████████████████████████
|
||||
2021 │████████████████████████████
|
||||
2022 │██████████████████████████
|
||||
2023 │█████████████████████████
|
||||
2024 │████████████████████████ ~8,005 (▼38% from 2013)
|
||||
└────────────────────────────────────────────────────
|
||||
|
||||
Source: OAMES January 2024 DME Supplier Tracking Data
|
||||
Note: AAHomecare tracking recorded the first time the number
|
||||
of reported locations fell below 9,000.
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
One in three traditional HME suppliers that existed in 2013
|
||||
is gone by 2024.
|
||||
```
|
||||
|
||||
A 38% decline over a decade is not attrition — it is structural contraction.
|
||||
The causes are layered: competitive bidding rate reductions, documentation
|
||||
burden increase, payer audit escalation, fraud-related moratoria, and the
|
||||
general inability of small operators to absorb increasing overhead without
|
||||
scale. Section 8 covers this in detail.
|
||||
|
||||
---
|
||||
|
||||
## 3. The Denial Crisis — Industry-Wide
|
||||
|
||||
### Rising Denial Rates
|
||||
|
||||
```
|
||||
INITIAL CLAIM DENIAL RATE — ALL HEALTHCARE PROVIDERS (2019–2025)
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
2019 │████████████████████░░░░░░░░░░ ~7%
|
||||
2020 │█████████████████████░░░░░░░░░ ~8%
|
||||
2021 │███████████████████████░░░░░░░ ~9%
|
||||
2022 │████████████████████████░░░░░░ ~10%
|
||||
2023 │█████████████████████████░░░░░ ~10.2%
|
||||
2024 │███████████████████████████░░░ 11.8% ◄ +16% YOY
|
||||
2025 │▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ 41% of providers
|
||||
│ report denial rates >10%
|
||||
└────────────────────────────────────────────────────────
|
||||
|
||||
Sources: Experian State of Claims 2025, Medical Economics 2025
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
Denials triggered by requests-for-information (RFIs) increased
|
||||
9% from 2022 to 2024. Denial amounts tied to RFI/medical necessity
|
||||
soared 70% to $450 average per denial in 2025.
|
||||
```
|
||||
|
||||
### Why DMEPOS Feels This Disproportionately
|
||||
|
||||
For hospitals and physician groups, a denied claim is a revenue cycle problem —
|
||||
painful, but recoverable through appeals, write-offs, or renegotiation.
|
||||
For a DMEPOS supplier, a denied claim on already-delivered equipment means:
|
||||
|
||||
- **Revenue not received** on a product already paid for
|
||||
- **Staff time** spent on appeals (often $25–$118 per appeal attempt)
|
||||
- **Patient continuity pressure** — the product is already in the patient's hands
|
||||
- **No cost-shift mechanism** — unlike hospitals, suppliers cannot adjust charges
|
||||
|
||||
---
|
||||
|
||||
## 4. CGM-Specific Denial Anatomy
|
||||
|
||||
CGM claims are particularly denial-prone because coverage requires a documented
|
||||
chain of events that spans multiple parties: the patient, the prescribing
|
||||
physician, the DME MAC (Medicare Administrative Contractor), and the supplier.
|
||||
A failure at any link — none of which the supplier controls — lands as a
|
||||
supplier liability.
|
||||
|
||||
### CGM Improper Payment Breakdown (Medicare 2024)
|
||||
|
||||
```
|
||||
MEDICARE CGM IMPROPER PAYMENT CAUSES — 2024 REPORTING PERIOD
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
Improper Payment Rate: 25.2%
|
||||
Projected Dollar Amount: $278.5 Million
|
||||
|
||||
Cause Breakdown:
|
||||
┌─────────────────────────────────┬──────────┐
|
||||
│ No documentation │ 67.6% │ ████████████████████
|
||||
│ Insufficient documentation │ 26.6% │ ████████
|
||||
│ Other errors │ 5.8% │ ██
|
||||
└─────────────────────────────────┴──────────┘
|
||||
|
||||
Source: CMS 2024 Medicare Fee-for-Service Supplemental
|
||||
Improper Payment Data
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
94.2% of CGM improper payments trace directly to documentation
|
||||
failures — not fraud, not medical necessity disputes, not billing
|
||||
code errors. Missing paperwork.
|
||||
```
|
||||
|
||||
### The Specific Documentation Chain CGM Requires
|
||||
|
||||
Every CGM claim requires all of the following to survive Medicare review:
|
||||
|
||||
```
|
||||
CGM CLAIM DOCUMENTATION CHAIN
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
INITIAL ORDER (one-time):
|
||||
✓ Written Order Prior to Delivery (WOPD)
|
||||
✓ Face-to-face practitioner visit WITHIN 6 months before order
|
||||
✓ Diagnosis documentation (diabetes type, insulin use)
|
||||
✓ Treating practitioner NPI — active, enrolled, correct
|
||||
✓ Standard Written Order (SWO) with required elements
|
||||
✓ Prior Authorization (required for all CGMs since Sept. 1, 2024)
|
||||
|
||||
REFILL / CONTINUED COVERAGE (every 6 months):
|
||||
✓ In-person or Medicare-approved telehealth visit with practitioner
|
||||
✓ Documentation of patient adherence to CGM regimen
|
||||
✓ Documentation of diabetes treatment plan review
|
||||
✓ Renewed prescription if prescriber has changed
|
||||
✓ Confirm NPI is still valid/active at time of claim
|
||||
|
||||
SUPPLIER-SPECIFIC:
|
||||
✓ Patient eligibility confirmed
|
||||
✓ Prior auth obtained and current
|
||||
✓ Correct HCPCS code for device model
|
||||
✓ Quantity within allowable per billing period
|
||||
✓ No duplicate claim for same billing period
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
Every item above is a potential denial trigger. The supplier
|
||||
is responsible for assembling this chain — but most of the
|
||||
information originates with people who are NOT the supplier.
|
||||
```
|
||||
|
||||
### The 6-Month Visit Problem
|
||||
|
||||
The Medicare 6-month visit requirement for continued CGM coverage is, in
|
||||
practice, the single largest source of preventable CGM denials for ongoing
|
||||
patients. Here is why:
|
||||
|
||||
- The requirement lives in the physician's schedule, not the supplier's workflow
|
||||
- Physicians do not automatically notify the supplier when a visit has or hasn't
|
||||
occurred
|
||||
- The supplier ships a refill order, the claim goes in, and weeks later it is
|
||||
denied because the visit that was supposed to happen in month 5 actually
|
||||
happened in month 7 — or did not happen at all
|
||||
- The patient has already been using the CGM supplies. Stopping them mid-cycle
|
||||
is a clinical safety issue.
|
||||
|
||||
**Signal CGM directly addresses this gap.** The coverage clock flags the
|
||||
upcoming 6-month visit window *before* the refill order ships, giving the
|
||||
supplier enough lead time to confirm with the prescriber's office.
|
||||
|
||||
---
|
||||
|
||||
## 5. The Hidden Cost: Free Product and Write-Offs
|
||||
|
||||
When a claim denies and a patient genuinely needs CGM supplies to manage
|
||||
insulin-dependent or otherwise CGM-qualifying diabetes, suppliers face a
|
||||
clinical and ethical bind that has a direct dollar cost:
|
||||
|
||||
### The Continuity of Care Obligation
|
||||
|
||||
Medicare billing rules explicitly state: *"If a Medicare beneficiary requires
|
||||
additional items during the billing period, the DME supplier must provide them
|
||||
at no charge to the beneficiary or to the Medicare program."*
|
||||
|
||||
This means that if a supplier ships CGM sensors in month 6 and the claim
|
||||
subsequently denies because the 6-month physician visit was not documented,
|
||||
**the supplier cannot go back and charge the patient** — they absorb the cost.
|
||||
|
||||
```
|
||||
COST EXPOSURE MODEL — SINGLE DENIED CGM REFILL ORDER
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
Typical monthly CGM supply order:
|
||||
┌──────────────────────────────────────┬──────────────┐
|
||||
│ CGM sensors (1 month supply) │ ~$150–$250 │
|
||||
│ Transmitter (amortized) │ ~$50–$75 │
|
||||
│ Delivery + handling │ ~$15–$25 │
|
||||
│ Billing staff time (pre-denial) │ ~$20–$35 │
|
||||
│ ├──────────────┤
|
||||
│ TOTAL cost at time of delivery │ ~$235–$385 │
|
||||
└──────────────────────────────────────┴──────────────┘
|
||||
|
||||
On denial:
|
||||
┌──────────────────────────────────────┬──────────────┐
|
||||
│ Appeal preparation (staff time) │ ~$25–$118 │
|
||||
│ Continuity product (if needed) │ ~$150–$250 │
|
||||
│ Write-off on denied order │ ~$235–$385 │
|
||||
│ ├──────────────┤
|
||||
│ TOTAL exposure per denied order │ ~$410–$753 │
|
||||
└──────────────────────────────────────┴──────────────┘
|
||||
|
||||
Supplier billing 500 CGM patients/month at a 25% improper
|
||||
payment rate = 125 at-risk orders/month = $51,250–$94,125
|
||||
in monthly exposure.
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
At a 25.2% CGM improper payment rate, a mid-size supplier
|
||||
is essentially running a charity program for one in four
|
||||
CGM patients — involuntarily.
|
||||
```
|
||||
|
||||
The phrase "free product" is not hyperbole. Suppliers regularly continue
|
||||
shipping CGM supplies to patients mid-appeal, mid-payer-review, and even after
|
||||
initial denials, because:
|
||||
|
||||
1. The patient is insulin-dependent and cannot safely gap their CGM use
|
||||
2. Stopping shipment triggers patient complaints and potential HIPAA/ADA issues
|
||||
3. Restarting a stopped CGM patient requires a new order cycle — more cost
|
||||
|
||||
This dynamic does not exist in pharmacy. A pharmacy simply declines to fill
|
||||
a prescription if insurance does not pay. DMEPOS suppliers often cannot do that
|
||||
with a patient who is actively managing insulin.
|
||||
|
||||
---
|
||||
|
||||
## 6. Payment Model Disruption: CGM Goes Rental
|
||||
|
||||
### The Old Model (Pre-2028)
|
||||
|
||||
Under the traditional Medicare DME benefit structure:
|
||||
- **CGM receivers**: One-time purchase payment (supplier gets paid once, patient
|
||||
owns the device after the initial claim)
|
||||
- **Insulin pumps**: Capped rental (Medicare pays monthly for 13 months, then
|
||||
the beneficiary owns the device)
|
||||
- **CGM sensors/supplies**: Billed monthly as a "supply allowance"
|
||||
|
||||
### The New Model (Effective 2028)
|
||||
|
||||
CMS finalized in the November 2025 DMEPOS CBP Final Rule a fundamental
|
||||
reclassification:
|
||||
|
||||
> *CMS finalizes reclassifying all continuous glucose monitors and insulin
|
||||
> infusion pumps under the **frequent and substantial servicing** payment
|
||||
> category, to be paid on a **monthly rental basis** under the DMEPOS
|
||||
> competitive bidding program.*
|
||||
|
||||
```
|
||||
CGM PAYMENT MODEL: BEFORE AND AFTER
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
BEFORE 2028:
|
||||
Month 0 │ [$$$] One-time device purchase claim → Medicare pays once
|
||||
Month 1 │ [$] Monthly supply claim
|
||||
Month 2 │ [$] Monthly supply claim
|
||||
...
|
||||
Month 12 │ [$] Monthly supply claim
|
||||
Patient owns device outright at some point
|
||||
|
||||
AFTER 2028 (Competitive Bidding Contracts):
|
||||
Month 0 │ [$] Monthly rental claim (device + supplies bundled)
|
||||
Month 1 │ [$] Monthly rental claim
|
||||
Month 2 │ [$] Monthly rental claim
|
||||
...
|
||||
Patient never "owns" device — can upgrade technology more
|
||||
frequently, but supplier carries perpetual billing relationship
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
The shift to rental increases monthly billing volume and
|
||||
complexity but also means more recurring denial opportunities
|
||||
at each monthly claim cycle.
|
||||
|
||||
CMS rationale: CGM technology changes too fast for a 5-year
|
||||
ownership model. Patient benefit is flexibility to upgrade.
|
||||
Industry objection: Administratively complex; compresses margins
|
||||
further when combined with CB rate reductions.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
### What This Means for Suppliers
|
||||
|
||||
The rental model creates **12 individual claim events per year per patient**
|
||||
where the old model had fewer high-value events. Each monthly rental claim
|
||||
carries its own documentation window, its own prior auth cycle, and its own
|
||||
denial risk. For a supplier managing 500 CGM patients, this is potentially
|
||||
6,000 individual billing cycles per year — each one a potential denial if the
|
||||
6-month visit isn't confirmed, the PA isn't current, or the NPI has changed.
|
||||
|
||||
**This multiplies the value of Signal CGM's worklist by a factor tied to monthly
|
||||
billing frequency.**
|
||||
|
||||
---
|
||||
|
||||
## 7. The UHC / Synapse Health Wrinkle
|
||||
|
||||
In a development that has fundamentally altered the managed care landscape for
|
||||
DME suppliers, UnitedHealthcare — the largest Medicare Advantage insurer in the
|
||||
country — has been systematically transferring DME order management to a
|
||||
third-party intermediary called **Synapse Health** since 2024.
|
||||
|
||||
### What Synapse Health Is
|
||||
|
||||
Synapse Health is not a payer and not a traditional pharmacy benefit manager.
|
||||
It functions as a **capitated DME management vendor** — UHC enters into a
|
||||
capitated arrangement with Synapse, which then manages order routing, network
|
||||
credentialing, and fulfillment logistics for standard DME items for UHC
|
||||
Medicare Advantage members.
|
||||
|
||||
### The Rollout Timeline
|
||||
|
||||
```
|
||||
UHC / SYNAPSE HEALTH GEOGRAPHIC ROLLOUT
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
2024 │ Initial pilots: Georgia (C-SNP), North Carolina (HMO/PPO)
|
||||
│
|
||||
Aug 1, 2025 │ HMO/PPO expansion:
|
||||
│ Alabama, South Carolina, Tennessee, Virginia
|
||||
│ C-SNP: Georgia added
|
||||
│
|
||||
Oct 1, 2025 │ HMO/PPO expansion:
|
||||
│ Illinois, Indiana, Kentucky, Michigan, Ohio, West Virginia
|
||||
│ C-SNP: Illinois added
|
||||
│
|
||||
Apr 1, 2026 │ HMO/PPO expansion:
|
||||
(NOW LIVE) │ Arkansas, Iowa, Kansas, Minnesota, Missouri, Nebraska,
|
||||
│ North Dakota, Oklahoma, South Dakota, Wisconsin
|
||||
│ C-SNP expansion:
|
||||
│ Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota,
|
||||
│ North Carolina, North Dakota, Ohio, Oklahoma, Wisconsin
|
||||
│ D-SNP:
|
||||
│ North Dakota, South Dakota, West Virginia
|
||||
│
|
||||
Future │ Additional states expected — pattern suggests national
|
||||
│ rollout is the strategic endpoint
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
Suppliers must join the Synapse Health network to continue
|
||||
serving UHC MA members in these states. Non-enrolled
|
||||
suppliers cannot receive orders for covered UHC MA members.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
### What This Means for a DMEPOS Supplier
|
||||
|
||||
1. **Network credentialing is now layered.** To serve a UHC Medicare Advantage
|
||||
member, a supplier must be credentialed with UHC *and* separately enrolled
|
||||
with Synapse Health. Non-enrollment = lost patient.
|
||||
|
||||
2. **Reimbursement rates are set by Synapse's capitated contract with UHC,**
|
||||
not negotiated directly between supplier and UHC. Suppliers accept Synapse
|
||||
terms or exit the UHC MA market segment.
|
||||
|
||||
3. **Order workflow changes.** Orders no longer come through UHC's standard
|
||||
channels — they route through Synapse's platform (mydme@synapsehealth.com,
|
||||
1.888.336.9363). Suppliers who haven't updated their intake workflow will
|
||||
experience order processing failures.
|
||||
|
||||
4. **Geographic expansion is ongoing.** A supplier who is compliant today may
|
||||
have a new compliance requirement with each quarterly expansion.
|
||||
|
||||
5. **UHC MA is not a niche book.** UHC is the largest Medicare Advantage
|
||||
insurer. For many small and mid-size DME suppliers, UHC MA patients represent
|
||||
20–40% of their CGM patient population. Disruption to this channel is a
|
||||
material revenue risk.
|
||||
|
||||
```
|
||||
SYNAPSE HEALTH IMPACT DIAGRAM
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
BEFORE:
|
||||
Patient → Prescriber → [UHC approval] → DMEPOS Supplier → Ship
|
||||
|
||||
AFTER (Synapse states):
|
||||
Patient → Prescriber → [UHC] → [Synapse Health routing] →
|
||||
└── Is supplier in Synapse network?
|
||||
YES: Order routed → DMEPOS Supplier → Ship
|
||||
NO: Order routed → Different supplier → Patient lost
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
UHC paused implementation in NC and GA briefly in early 2025
|
||||
due to supplier pushback, then resumed. The program has not
|
||||
been rescinded — it has only expanded since the pause.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
The Synapse wrinkle is separate from — and in addition to — the traditional
|
||||
PA/documentation denial risk. It is a **patient access gatekeeping mechanism**
|
||||
that operates before the claim is even submitted.
|
||||
|
||||
---
|
||||
|
||||
## 8. Systematic Squeeze: Are Small Suppliers Being Pushed Out?
|
||||
|
||||
The evidence is consistent: the structural environment for small and independent
|
||||
DMEPOS suppliers has deteriorated materially over the last decade, and the
|
||||
compression is accelerating in 2026.
|
||||
|
||||
### The Compression Forces
|
||||
|
||||
```
|
||||
PRESSURE VECTORS ON SMALL DMEPOS SUPPLIERS
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
MARGIN COMPRESSION
|
||||
──────────────────
|
||||
Competitive Bidding (CB) rate reductions → Below-cost bids required
|
||||
to win CB contracts. Earlier CB rounds caused widespread closures.
|
||||
|
||||
CB 2028: CGMs, insulin pumps, OTS braces, ostomy, urological all
|
||||
included. Bidding window opens late Summer/Fall 2026. Margins will
|
||||
compress further for contract winners; losers exit the market.
|
||||
|
||||
DOCUMENTATION BURDEN
|
||||
────────────────────
|
||||
PA required for all CGMs since Sept. 1, 2024.
|
||||
Prior authorization expansion effective April 13, 2026.
|
||||
Annual accreditation surveys now required (previously every 3 years).
|
||||
36-month ownership change restrictions added in 2026.
|
||||
|
||||
Each new compliance layer costs staff time that small suppliers
|
||||
absorb at a higher per-patient rate than large ones.
|
||||
|
||||
PAYER RESTRUCTURING
|
||||
───────────────────
|
||||
UHC/Synapse model effectively requires dual-network credentialing.
|
||||
Other large MA plans watching UHC's model closely.
|
||||
|
||||
ENROLLMENT CONTROLS
|
||||
───────────────────
|
||||
CMS nationwide Medicare DMEPOS enrollment moratorium: Feb. 27, 2026.
|
||||
Florida Medicaid DMEPOS moratorium: March 20, 2026.
|
||||
Explicitly framed as a "fraud crackdown."
|
||||
Practical effect: New entrants blocked; consolidation accelerates.
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
### Supplier Count Trajectory
|
||||
|
||||
```
|
||||
THE ATTRITION MATH
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
Traditional HME locations: ~13,000 (2013) → ~8,005 (2024)
|
||||
Net loss over 10 years: ~5,000 supplier locations
|
||||
Rate: ~500 supplier locations per year
|
||||
|
||||
Post-CB Round 2021 + PA expansion + Synapse + 2026 moratoria:
|
||||
Rate is likely accelerating, not stabilizing.
|
||||
|
||||
Who exits first?
|
||||
┌─────────────────────────────────────────────────────────────┐
|
||||
│ Small suppliers (<$3.5M revenue) │
|
||||
│ → Cannot absorb CB bid bond requirements ($50K per CBA) │
|
||||
│ → Cannot staff PA workflows at competitive cost │
|
||||
│ → Cannot complete Synapse credentialing without IT staff │
|
||||
│ → Cannot survive a 3–5 month denial + appeal cycle │
|
||||
│ │
|
||||
│ Mid-size suppliers ($3.5M–$20M revenue) │
|
||||
│ → Under margin pressure but have scale to adapt │
|
||||
│ → Often the Signal CGM buyer profile │
|
||||
│ │
|
||||
│ Large regional / national suppliers │
|
||||
│ → Win CB contracts, absorb Synapse requirements with ease │
|
||||
│ → Consolidators — acquiring smaller suppliers' books │
|
||||
└─────────────────────────────────────────────────────────────┘
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
The US healthcare system is not killing DMEPOS suppliers
|
||||
directly — it is creating conditions where only those with
|
||||
scale survive, which is functionally equivalent for small
|
||||
operators.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
### The Story the Numbers Tell
|
||||
|
||||
The DMEPOS sector is experiencing what might be called a **regulatory ratchet**:
|
||||
each new compliance layer is individually justifiable (PA reduces waste; CB
|
||||
reduces Medicare cost; moratoria prevent fraud enrollment), but the cumulative
|
||||
effect on small operators is insurmountable overhead. Large suppliers can hire
|
||||
the billing staff, purchase the compliance software, and complete the network
|
||||
credentialing. Small ones cannot.
|
||||
|
||||
The paradox is that the suppliers most likely to exit are also the ones most
|
||||
likely to be providing personalized, community-level service to the patients who
|
||||
need it most. CGM patients receiving supplies from a local independent supplier
|
||||
— who knows them by name, calls when shipments are due, and troubleshoots
|
||||
device issues — lose access to that relationship when the supplier closes.
|
||||
|
||||
---
|
||||
|
||||
## 9. Patient Outcomes: Why DMEPOS Channel Matters
|
||||
|
||||
The most important counterargument to the consolidation trend — and a key Signal
|
||||
CGM positioning asset — is the clinical evidence on patient outcomes by sourcing
|
||||
channel.
|
||||
|
||||
### DME Channel vs. Pharmacy: The Study
|
||||
|
||||
A 2024 peer-reviewed retrospective claims analysis published in *Clinical
|
||||
Diabetes* (American Diabetes Association) and JMIR Diabetes compared CGM
|
||||
adherence and healthcare costs for patients sourcing CGMs from DME suppliers
|
||||
versus pharmacy channels.
|
||||
|
||||
```
|
||||
CGM ADHERENCE: DME CHANNEL vs. PHARMACY CHANNEL (12-MONTH DATA)
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
Adherence Rate at 12 Months:
|
||||
┌──────────────────────────────────────────────────────────┐
|
||||
│ │
|
||||
│ DME Channel 78% ████████████████████████████████░░ │
|
||||
│ Pharmacy 64% ██████████████████████████░░░░░░░░ │
|
||||
│ │
|
||||
│ DME advantage: +14 percentage points │
|
||||
│ DME patients: 23% MORE likely to adhere │
|
||||
│ │
|
||||
└──────────────────────────────────────────────────────────┘
|
||||
|
||||
Healthcare Cost at 12 Months:
|
||||
DME Channel patients paid 35% LESS in overall healthcare costs
|
||||
compared to pharmacy-sourced CGM patients.
|
||||
|
||||
Reinitiation Rate:
|
||||
DME-sourced patients were MORE likely to restart CGM use after
|
||||
a gap period compared to pharmacy-sourced patients.
|
||||
|
||||
Physician Preference:
|
||||
73% of endocrinologists prefer DME suppliers over other
|
||||
distribution models due to superior end-user support.
|
||||
|
||||
Sources: AJMC / Clinical Diabetes (ADA) 2024,
|
||||
JMIR Diabetes 2024 (PMC12304568)
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
The DME channel produces better clinical outcomes because
|
||||
DME suppliers specialize in equipment management, patient
|
||||
education, and ongoing support — services a pharmacy counter
|
||||
cannot replicate.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
### Why This Matters for Signal CGM
|
||||
|
||||
The patient outcome evidence is a strategic asset for DMEPOS suppliers in two
|
||||
directions:
|
||||
|
||||
1. **Legislative / advocacy context:** DMEPOS suppliers can legitimately argue
|
||||
that policies driving them out of the market (CB margin compression, Synapse
|
||||
gatekeeping, enrollment moratoria) harm patients, not just suppliers. The
|
||||
data supports this.
|
||||
|
||||
2. **Signal CGM ROI argument:** A supplier who uses Signal CGM to prevent
|
||||
coverage gaps keeps patients on their CGM continuity, which produces the
|
||||
adherence advantage. Helping a patient stay covered is not just a billing
|
||||
optimization — it is a clinical outcome driver.
|
||||
|
||||
---
|
||||
|
||||
## 10. The Regulatory Stack — 2026 Urgency Drivers
|
||||
|
||||
```
|
||||
ACTIVE REGULATORY PRESSURES AS OF APRIL 2026
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
LIVE NOW
|
||||
────────
|
||||
● PA Required for ALL CGMs (since Sept. 1, 2024)
|
||||
Every initial CGM order must have prior authorization.
|
||||
New supply codes (A4238) added to Master List Jan. 2026.
|
||||
|
||||
● PA Expansion — April 13, 2026 (this month)
|
||||
7 additional HCPCS codes added to required prior auth list.
|
||||
New exemption process: suppliers with ≥10 requests and
|
||||
≥90% provisional affirmation rate may qualify for exemption.
|
||||
First exemption cycle begins June 1, 2026.
|
||||
|
||||
● Nationwide Medicare DMEPOS Enrollment Moratorium (Feb. 27, 2026)
|
||||
No new supplier enrollments for 6 months.
|
||||
New/change-of-majority-ownership applications denied.
|
||||
Incumbent suppliers have protected market position —
|
||||
and rising per-patient management burden.
|
||||
|
||||
● Florida Medicaid Moratorium (March 20, 2026)
|
||||
6-month moratorium on new Medicaid DMEPOS supplier enrollment.
|
||||
Incumbent Florida suppliers face rising patient load.
|
||||
|
||||
● Annual Accreditation Surveys (effective Jan. 1, 2026)
|
||||
Previously required every 3 years; now annual.
|
||||
36-month majority ownership change restrictions added.
|
||||
Administrative overhead up across the board.
|
||||
|
||||
● UHC/Synapse Health Expansion (April 1, 2026)
|
||||
10 additional states now require Synapse enrollment.
|
||||
Suppliers not in network lose access to UHC MA patients.
|
||||
|
||||
COMING
|
||||
──────
|
||||
● CB 2028 Bidding Window (opens late Summer/Fall 2026)
|
||||
CGMs, insulin pumps, ostomy, urological, OTS braces included.
|
||||
Suppliers must bid competitively or exit CB contract areas.
|
||||
18–24 months to prepare cost structures and denial workflows
|
||||
before rates compress further.
|
||||
|
||||
● CGM Monthly Rental Reclassification (effective Jan. 1, 2028)
|
||||
All CGMs move to "frequent and substantial servicing" category.
|
||||
Monthly billing replaces purchase-based model.
|
||||
12× annual claim events per patient vs. current model.
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
Every item above increases the documentation burden, the billing
|
||||
complexity, or the margin pressure on DMEPOS suppliers — and
|
||||
increases the value of a tool that automates coverage tracking.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 11. The Workload Impact Model
|
||||
|
||||
This is the core Signal CGM value visualization for sales and discovery calls.
|
||||
|
||||
```
|
||||
SUPPLIER STAFF TIME: REACTIVE vs. PROACTIVE WORKFLOW
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
Staff Hours/Week
|
||||
│
|
||||
│ REACTIVE (without Signal CGM)
|
||||
High │
|
||||
│ ██████████████████
|
||||
│ ████████████████████████
|
||||
│ ██████████████████████████████
|
||||
│ █████████████████████████████████████
|
||||
│ ████████████████████████████████████████████
|
||||
─────┼────────────────────────────────────────────────────▶ Month
|
||||
│ ↑ Appeals backlog grows as denials compound
|
||||
│ Each unresolved denial breeds the next
|
||||
│ Staff is reactive — putting out fires, not preventing them
|
||||
|
||||
PROACTIVE (with Signal CGM)
|
||||
│
|
||||
Low │ ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓
|
||||
│ Flat, predictable outreach workload
|
||||
│ Staff works off a sorted worklist each morning
|
||||
│ Highest-urgency patients at the top
|
||||
│ Outreach happens before the claim, not after the denial
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
THE TWO CURVES (Discovery Call Visual)
|
||||
|
||||
Staff Time
|
||||
│\
|
||||
│ \ CURVE A: Reactive appeals/denials workload
|
||||
│ \ Starts HIGH — every backlogged denial requires staff time
|
||||
│ \ Trends DOWN as proactive management takes hold
|
||||
│ \
|
||||
│ \ ← Crossover = ROI moment (typically Month 3–5)
|
||||
│ \_____________________________________
|
||||
│
|
||||
│ ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓
|
||||
│ CURVE B: Proactive Signal CGM outreach workload
|
||||
│ Starts MANAGEABLE — sorted worklist, predictable volume
|
||||
│ Stays FLAT — does not grow with patient count
|
||||
│
|
||||
└──────────────────────────────────────────────▶ Month
|
||||
1 2 3 4 5 6 7 8 9 10 11 12
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
The crossover is the ROI moment to anchor on discovery calls.
|
||||
Signal CGM does not eliminate work. It restructures it —
|
||||
from uncontrolled reactive fire-fighting to controlled,
|
||||
predictable outreach.
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## 12. Contrary Opinions — The Other Side of the Story
|
||||
|
||||
A fair research document must include the legitimate criticisms of the DMEPOS
|
||||
sector. These are real, documented, and used by payers and regulators to
|
||||
justify the compliance burden suppliers carry.
|
||||
|
||||
### The Fraud Record Is Real
|
||||
|
||||
The OIG and DOJ have documented a consistent pattern of DMEPOS fraud over
|
||||
decades, and it is not trivial:
|
||||
|
||||
| Enforcement Action | Details |
|
||||
|--------------------|---------|
|
||||
| OIG improper payments | $22.7M in improper payments over 7 years for DME during inpatient stays |
|
||||
| Overpayment (2015–2017) | $34M in supplier overpayments found in audit |
|
||||
| Continued overpayment | $4.5M overpayments found in 2020–2024 follow-up audit |
|
||||
| Annual Medicare DME spend | $7B+ annually — the size of the target |
|
||||
| 2026 moratorium framing | CMS explicitly frames as "major crackdown on fraud" |
|
||||
|
||||
### The Specific Fraud Patterns That Taint the Sector
|
||||
|
||||
**Billing for items never delivered.** Some suppliers have submitted Medicare
|
||||
claims for DME that was never actually provided to the beneficiary, or submitted
|
||||
bills without the patient's knowledge or consent.
|
||||
|
||||
**Kickback arrangements.** Some providers accepted kickbacks from suppliers to
|
||||
prescribe DMEPOS items that were not medically necessary. This polluted the
|
||||
prescriber-supplier relationship that honest suppliers depend on.
|
||||
|
||||
**Identity theft and patient data exploitation.** In some cases, patient
|
||||
information was used to open fraudulent DME accounts entirely without the
|
||||
patient's involvement.
|
||||
|
||||
**Credential farming.** Newly enrolled suppliers with no actual patient
|
||||
population billed extensively and then folded — a pattern that drove the
|
||||
enrollment moratorium model.
|
||||
|
||||
### The Counterargument (Structural, Not Exculpatory)
|
||||
|
||||
The fraud that exists in DMEPOS is real but concentrated. It is predominantly
|
||||
perpetrated by:
|
||||
- **Shell companies** with no operational patient base
|
||||
- **Organized fraud rings** exploiting the lag time between claim submission
|
||||
and audit detection
|
||||
- **Referral kickback networks** involving physicians and marketers, not
|
||||
frontline clinical suppliers
|
||||
|
||||
Legitimate, established DMEPOS suppliers — particularly those serving
|
||||
real patient populations with real clinical needs like CGM — bear the
|
||||
compliance cost of the fraud perpetrated by bad actors they have nothing to do
|
||||
with. The documentation requirements, prior authorization rules, enrollment
|
||||
scrutiny, and audit risk that legitimate suppliers navigate daily exist, in
|
||||
large part, because of fraud committed by entities that were never legitimate
|
||||
suppliers in the first place.
|
||||
|
||||
### Legitimate Criticism: Documentation Burden as Competitive Barrier
|
||||
|
||||
A more structural criticism comes from health economists and patient advocates:
|
||||
the complexity of DMEPOS billing documentation has become so high that it now
|
||||
functions as a barrier to *legitimate* competition, not just fraud prevention.
|
||||
Suppliers who cannot afford billing staff or compliance software exit the
|
||||
market — not because they are fraudulent, but because compliance overhead
|
||||
consumes margin. The result is consolidation toward large operators who can
|
||||
absorb the overhead, which is arguably the opposite of the competitive outcome
|
||||
policymakers claim to want.
|
||||
|
||||
### The Other Side of "Patient Outcomes"
|
||||
|
||||
While the DME channel does show superior CGM adherence (Section 9), critics
|
||||
note:
|
||||
|
||||
- **Selection bias:** DME-sourced CGM patients may be more engaged in their
|
||||
care to begin with (they navigated the DME intake process vs. a simple
|
||||
pharmacy pickup)
|
||||
- **Pharmacy channel improvements:** Retail pharmacies have invested heavily
|
||||
in diabetes services and clinical pharmacist programs; the 2024 data may
|
||||
not fully reflect these improvements
|
||||
- **Consolidation quality risk:** The DME channel advantage is attributed to
|
||||
personalized support from specialized staff — but as consolidation replaces
|
||||
local suppliers with national operators, that personalization advantage may
|
||||
erode, making the channel comparison less favorable over time
|
||||
|
||||
---
|
||||
|
||||
## 13. Signal CGM Positioning Summary
|
||||
|
||||
```
|
||||
SIGNAL CGM VALUE STACK
|
||||
────────────────────────────────────────────────────────────────────
|
||||
|
||||
PROBLEM (proven, data-backed)
|
||||
├── CGM improper payment rate: 25.2% / $278.5M annually
|
||||
├── 94.2% of those failures: documentation errors, not fraud
|
||||
├── Supplier bears full cost on already-delivered product
|
||||
├── 6-month visit requirement: predictable, trackable, preventable
|
||||
├── Monthly rental model (2028): 12× annual billing events = 12×
|
||||
│ denial opportunities per patient per year
|
||||
└── UHC/Synapse: new credentialing layer creating patient access risk
|
||||
|
||||
SOLUTION (Level 1 scope)
|
||||
├── Coverage clock per patient: tracks wear-day rules by device/payer
|
||||
├── 6-month visit flag: surfaces BEFORE refill ships, not after deny
|
||||
├── Daily sorted worklist: OUT_OF_COVERAGE, VISIT_DUE, REFILL_WINDOW
|
||||
├── Minimal PHI surface: patient_id only, no names/SSNs/DOBs
|
||||
└── Self-hosted: data never leaves supplier's environment
|
||||
|
||||
URGENCY (why act now, not later)
|
||||
├── PA expansion: live April 13, 2026
|
||||
├── CB 2028 bidding window: opens late Summer/Fall 2026
|
||||
├── Enrollment moratoria: incumbents have protected position but
|
||||
│ rising per-patient burden — tools are the only scale lever
|
||||
└── Monthly rental model coming: front-load compliance infrastructure
|
||||
before billing complexity doubles
|
||||
|
||||
TARGET BUYER
|
||||
├── Mid-size supplier: 200–2,000 CGM patients/month
|
||||
├── Currently managing coverage in spreadsheets or Brightree fields
|
||||
└── Feels the denial problem but doesn't have a systematic fix
|
||||
|
||||
────────────────────────────────────────────────────────────────────
|
||||
```
|
||||
|
||||
---
|
||||
|
||||
## Sources
|
||||
|
||||
Research compiled April 2026 from:
|
||||
|
||||
- [State of Claims 2025 — Experian Healthcare](https://www.experian.com/blogs/healthcare/state-of-claims-2025/)
|
||||
- [Healthcare Denial Rate Statistics 2026 — Aptarro](https://www.aptarro.com/insights/us-healthcare-denial-rates-reimbursement-statistics)
|
||||
- [50+ US Healthcare Denial Rates & Reimbursement Statistics — Aptarro](https://www.aptarro.com/insights/us-healthcare-denial-rates-reimbursement-statistics)
|
||||
- [CMS Glucose Monitoring Compliance Tips](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies)
|
||||
- [CMS Glucose Monitor Policy Article A52464](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52464)
|
||||
- [FAQs on CGM Coverage Criteria — ADA](https://diabetes.org/advocacy/cgm-continuous-glucose-monitors/faqs-medicare-coverage)
|
||||
- [Medicare DMEPOS Prior Authorization Expansion April 13, 2026 — HCIntellect](https://www.hcintellect.com/post/medicare-dmepos-prior-authorization-expansion-effective-april-13-2026)
|
||||
- [CGM Adherence and Costs Improve With DME Channel — AJMC](https://www.ajmc.com/view/cgm-adherence-and-costs-improve-with-dme-channel-over-pharmacy)
|
||||
- [Impact of CGM Sourcing on Adherence and Costs — PMC/ADA Clinical Diabetes](https://pmc.ncbi.nlm.nih.gov/articles/PMC12304568/)
|
||||
- [JMIR Diabetes — CGM Sourcing Retrospective Claims Analysis](https://diabetes.jmir.org/2024/1/e58832/)
|
||||
- [AAHomecare — DME Supplier CGM Access Resources](https://www.hmenews.com/article/aahomecare-launches-resources-to-highlight-role-of-dme-suppliers-in-cgm-access)
|
||||
- [Synapse Health Will Manage DME Orders in Select States — UHCprovider.com](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html)
|
||||
- [UHC/Synapse Health Agreement Expands — HME News](https://www.hmenews.com/article/unitedhealthcare-synapse-health-agreement-expands-to-additional-states)
|
||||
- [Synapse Health: 'There's Something in This for Everyone' — HME News](https://www.hmenews.com/article/synapse-health-there-s-something-in-this-for-everyone)
|
||||
- [UHC Pauses MA Model in NC, GA — HomeCare Magazine](https://www.homecaremag.com/news/unitedhealthcare-pauses-implementation-new-ma-model-nc-ga)
|
||||
- [OAMES January 2024 DME Supplier Tracking Data](https://www.oames.org/aws/OAMES/pt/sd/news_article/556819/_PARENT/layout_details/false)
|
||||
- [Trump Admin Freezes DMEPOS Enrollment — MDDIOnline](https://www.mddionline.com/regulatory-quality/trump-launches-moratorium-on-new-durable-medical-equipment-suppliers)
|
||||
- [CMS DMEPOS Enrollment Moratorium — Greenberg Traurig](https://www.gtlaw.com/en/insights/2026/2/cms-announces-medicare-dmepos-supplier-enrollment-moratorium)
|
||||
- [CMS DMEPOS Competitive Bidding Final Rule — Applied Policy (Nov. 2025)](https://www.appliedpolicy.com/wp-content/uploads/DMEPOS-CBP-final-rule-first-night-summary-11.28.2025.pdf)
|
||||
- [DMEPOS CBP Proposed Rule Summary — Applied Policy (June 2025)](https://www.appliedpolicy.com/wp-content/uploads/DMEPOS-Competitive-Bidding-Program-proposed-rule-summary-6.30.2025.pdf)
|
||||
- [Capped Rental Items — Noridian DME MAC](https://med.noridianmedicare.com/web/jddme/topics/payment-categories/capped-rental)
|
||||
- [5 Most Common DME Claim Denials — WonderWS](https://wonderws.com/5-most-common-dme-claim-denials-and-how-to-fix-them/)
|
||||
- [OIG White Paper: Fraud, Waste, Abuse in DMEPOS](https://oig.hhs.gov/reports/work-plan/browse-work-plan-projects/white-paper-fraud-waste-and-abuse-related-to-durable-medical-equipment-in-medicare/)
|
||||
- [OIG: Medicare Improperly Paid $22.7M for DME During Inpatient Stays](https://oig.hhs.gov/reports/all/2025/medicare-improperly-paid-suppliers-227-million-over-7-years-for-durable-medical-equipment-prosthetics-orthotics-and-supplies-provided-to-enrollees-during-inpatient-stays/)
|
||||
- [Trump Administration Targets DME in Fraud Crackdown — MedTech Dive](https://www.medtechdive.com/news/trump-administration-targets-dme-suppliers-in-fraud-crackdown/813375/)
|
||||
- [HME News: CMS Enrollment Freeze Chills Deals, Bidding Prep (April 2026)](https://digital.hmenews.com/publication/?i=862439&article_id=5129647&view=articleBrowser)
|
||||
- [Federal Register: DMEPOS Enrollment Moratorium (Feb. 27, 2026)](https://www.federalregister.gov/documents/2026/02/27/2026-03971/medicare-medicaid-and-childrens-health-insurance-programs-announcement-of-nationwide-temporary)
|
||||
- [CMS Prior Authorization Process for DMEPOS](https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/prior-authorization-and-pre-claim-review-initiatives/prior-authorization-process-certain-durable-medical-equipment-prosthetics-orthotics-and-supplies)
|
||||
- [CMS Expands DMEPOS Oversight: 2026 Master List Update — Bristol HCS](https://www.bristolhcs.com/blog/blog-detail/cms-expands-medicare-dmepos-oversight-what-providers-must-know-about-the-2026-master-list-update)
|
||||
- [UHC Medicare Advantage CGM Through Pharmacy POS — ManagedCareCGM](https://www.managedcarecgm.com/uhc-grants-medicare-advantage-member-access-to-cgm-through-pharmacy-pos/)
|
||||
- [What is DME Billing? 2026 — NikoHealth](https://nikohealth.com/what-is-dme-billing/)
|
||||
- [Rental vs. Purchase DME Billing — 24/7 Medical Billing Services](https://www.247medicalbillingservices.com/blog/rental-vs-purchase-dme-billing-guidelines-common-payer-pitfalls)
|
||||
1165
capture-signal-cgm-assets.sh
Executable file
1165
capture-signal-cgm-assets.sh
Executable file
File diff suppressed because it is too large
Load diff
5
mempalace.yaml
Normal file
5
mempalace.yaml
Normal file
|
|
@ -0,0 +1,5 @@
|
|||
wing: signal_cgm
|
||||
rooms:
|
||||
- name: general
|
||||
description: All project files
|
||||
keywords: []
|
||||
Loading…
Reference in a new issue